Dicerna to Begin Clinical Development of DCR-A1AT for Treatment of Patients with Alpha-1 Antitrypsin…
DicernaTMPharmaceuticals announced it submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA) last week to conduct a first-in-human Phase…
Read More...
Read More...
